People · Operator
Named in public records as an officer, director or promoter · active 2014–2021 · Biotechnology, Pharmaceuticals, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Viracta Therapeutics, INC. | — | Biotechnology | Series C | $164.6M | $2.1B | 2020 |
| Seres Health, Inc. | — | Pharmaceuticals | Series C | $123.6M | $2.3B | 2014 |
| X-Vax Technology, Inc. | — | Biotechnology | Series C | $56.6M | $2.3B | 2016 |
| CollPlant Biotechnologies Ltd | — | Biotech / Pharma | Series A | $17.8M | $9.9M | 2020 |
Roger Pomerantz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Roger Pomerantz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Roger J. Pomerantz | 2 | 4 |
| Patrick Soon-Shiong | 1 | 16 |
| Peter Barton Hutt | 1 | 14 |
| Isaac Blech | 1 | 14 |
| Noubar Afeyan | 1 | 9 |
| Robert Ruffolo | 1 | 8 |
| Ivor Royston | 1 | 7 |
| Werner Cautreels | 1 | 5 |
| Hugh Evans | 1 | 4 |
| James Woody | 1 | 4 |
| Brian D. Finn | 1 | 4 |
| Paul Goddard | 1 | 4 |
| Armen Shanafelt | 1 | 3 |
| Frederick Dotzler | 1 | 3 |
| Ronald Berenson | 1 | 3 |
| Barry Simon | 1 | 3 |
| David Berry | 1 | 3 |
| Alisa Lask | 1 | 3 |
| James N. Woody | 1 | 3 |
| Wayne Roe | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.